FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

PODD

Insulet CorporationNASDAQ · Health Care Equipment · Health Care
Previous close
149.68
Change
−2.82 / −1.85%
FinDog View
Neutral
52-Week Range ?
126.40 – 354.88
P/E (TTM) ?
28.2
Forward P/E ?
19.1
Based on consensus earnings for the next 12 months
Market Cap
$10.5B
1M
+14.72%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.1M / 1.3M
0.87× average
Latest earnings analysisFY2026 Q2Reported 2026-08-05

Insulet Q2 2026: revenue up 23.5% to $801.7 million, but FY outlook trimmed

Insulet's second quarter was strong on the income statement and softer on the outlook: revenue rose 23.5% to $801.7 million and adjusted earnings per share climbed 41.5%, while management trimmed full-year constant-currency revenue growth to 20%–22%. Read the scorecard for the growth and margin detail, then the guidance section, where the type 2 diabetes rollout is the story.

Read the full analysis →
Revenue$0.80BYoY +23.50%
EPS (non-GAAP)$1.66Beatest. $1.48
Next-day move+4.53%

Price History

Closing price · USD1M6M1Y5Y
100200300400EFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 EarningsEFY25 Q3 Earnings2025-102026-012026-052026-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 33.61M6M1Y5Y
20304050602026-042026-062026-082026-092026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-04
in 3 days · time TBD
Consensus EPS
$1.62
Last quarter EPS $1.66
Avg. next-day move over the last 6 reports
±6.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 6 of its 5-year rangeCheap
5-year range 27.7 – 172.2 · Median 56.5
Last 4 quarters: $330M in buybacks + $0 in dividends, 3.15% of market cap combined
P/E (TTM)
28.2
P/B
7.0
P/S
3.5
PEG
0.82
Earnings Reaction
Over the last 6 reports, the stock moved ±6.2% on average on the first trading day after, rising 4 times
Most recent +4.53%
Volatility & Correlation
1-year beta 0.25 · Correlation with S&P 500 0.07Low beta
Annualized volatility 45% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 1 · $0.16MSell 0 · $0.00MNet buying $0.16M
  • 08-21McEvoy AshleyPresident and CEOBuy$0.16M1,100 shares · Avg price 147.47
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q20.80+23.5%70.2%0.130.100.061.37
FY2026 Q10.76+33.9%69.4%0.120.090.091.30
FY2025 Q40.78+31.2%72.5%0.150.100.051.42
FY2025 Q30.71+29.9%72.2%0.120.090.101.24
FY2025 Q20.65+32.9%69.7%0.120.020.180.32
FY2025 Q10.57+28.8%71.9%0.090.040.050.50
FY2024 Q40.60+17.2%72.1%0.110.100.091.38
FY2024 Q30.54+25.7%69.3%0.090.080.081.08
FY2024 Q20.49+23.2%67.7%0.050.190.062.59
FY2024 Q10.44+23.3%69.5%0.060.050.070.73
FY2023 Q40.51+21.9%70.9%0.110.100.021.47
FY2023 Q30.43+27.0%67.8%0.050.050.040.74

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView